Dr. Cantu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-648-0921Fax+1 214-648-0952
Summary
- Dr. Miguel Cantu is a pathologist in Dallas, TX and is affiliated with the a University of Texas Southwestern. He received his medical degree from McGovern Medical School. He completed residency in Anatomic and Clinical Pathology and Hematopathology fellowship at New York Presbyterian-Weill Cornell and Molecular Genetic Pathology fellowship at UTSW.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Molecular Genetic Pathology, 2021 - 2022
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematopathology, 2020 - 2021- New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 2016 - 2020
McGovern Medical School at UTHealthClass of 2016
Certifications & Licensure
TX State Medical License 2022 - 2025
NY State Medical License 2020 - 2022- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Hematology
- American Board of Pathology Molecular Genetic Pathology
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- 1 citationsGenomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype.Ruifang Zheng, Franklin Fuda, Jeffrey R Gagan, Olga K Weinberg, Prasad Koduru
Leukemia Research Reports. 2024-01-01 - Pancytopenia and haematopoietic precursor vacuolisation in an infant: Clues to Pearson syndrome.Jordan H Driskill, Miguel Dario Cantu, Jessica Garcia, Kathryn E Dickerson, Weina Chen
British Journal of Haematology. 2023-09-01 - 1 citationsPresence but not number of secondary type mutations influences outcome in de novo AML without MDS-associated or recurring cytogenetic abnormalities.Olga K Weinberg, Miguel D Cantu, Jeffrey Gagan, Yazan F Madanat, Daniel A Arber
Ejhaem. 2023-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
